# Continued Treatment for Participants Enrolled in Studies of BXQ-350

> **NCT04404569** · PHASE1 · TERMINATED · sponsor: **Bexion Pharmaceuticals, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BXQ-350

## Key facts

- **NCT ID:** NCT04404569
- **Lead sponsor:** Bexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-08
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404569, "Continued Treatment for Participants Enrolled in Studies of BXQ-350". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04404569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*